CACCESE, MARIO
 Distribuzione geografica
Continente #
NA - Nord America 461
EU - Europa 376
AS - Asia 168
OC - Oceania 2
Totale 1.007
Nazione #
US - Stati Uniti d'America 461
CN - Cina 158
GB - Regno Unito 152
IE - Irlanda 62
SE - Svezia 52
DE - Germania 32
FR - Francia 30
IT - Italia 30
FI - Finlandia 6
UA - Ucraina 6
VN - Vietnam 3
AU - Australia 2
CH - Svizzera 2
IR - Iran 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BG - Bulgaria 1
IN - India 1
JP - Giappone 1
RO - Romania 1
UZ - Uzbekistan 1
Totale 1.007
Città #
Chandler 170
Southend 146
Dublin 62
Woodbridge 33
Beijing 30
Houston 23
Ashburn 20
Ann Arbor 18
Jacksonville 18
Shenyang 18
Jinan 15
New York 15
Lawrence 14
Princeton 14
Nanjing 13
Verona 13
Wilmington 13
Tianjin 12
Guangzhou 7
Hebei 6
Ningbo 6
Siegen 6
Sindelfingen 5
Taizhou 5
Zhengzhou 5
Hangzhou 4
Nanchang 4
Augusta 3
Detroit 3
Lancaster 3
Redmond 3
Taiyuan 3
Changsha 2
Fuzhou 2
Haikou 2
London 2
Norwalk 2
Redwood City 2
Seattle 2
Sossano 2
Adliswil 1
Ardabil 1
Austin 1
Baku 1
Bologna 1
Buffalo 1
Böblingen 1
Cascina 1
Cattolica 1
Des Moines 1
Dong Ket 1
Dongguan 1
Dubai 1
Fairfield 1
Fremont 1
Kashan 1
Mehlingen 1
Melbourne 1
Negrar 1
Newark 1
Nürnberg 1
Phoenix 1
Riva 1
San Francisco 1
Sant'Ambrogio di Valpolicella 1
Sofia 1
Sydney 1
Tashkent 1
Tokyo 1
Washington 1
Zurich 1
Totale 757
Nome #
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 107
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 104
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 99
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 85
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 84
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 81
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 79
A molecular signature associated with prolonged survival in glioblastoma patients treated with Regorafenib 70
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 67
Do immune checkpoint inhibitors need new studies methodology? 60
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 58
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 56
Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study 42
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 37
Totale 1.029
Categoria #
all - tutte 3.130
article - articoli 2.901
book - libri 0
conference - conferenze 229
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.260


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201912 0 0 0 0 0 0 0 0 0 0 2 10
2019/2020106 14 2 0 11 12 10 15 3 11 8 3 17
2020/2021114 18 11 16 16 11 5 2 2 0 5 21 7
2021/2022127 10 54 2 1 12 1 1 6 2 2 2 34
2022/2023371 16 47 14 99 28 92 1 25 43 0 2 4
2023/2024107 6 16 7 11 15 27 4 10 4 7 0 0
Totale 1.029